{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:41:46Z","timestamp":1790804506694,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001314","name":"University of Durham","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001314","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Systemic sclerosis (SSc) is an autoimmune connective tissue disease in which there is an activation of fibroblast to a myofibroblast that secretes huge amounts of extracellular matrix. Currently, no treatment exists that modifies the fibrosis elements and new therapeutic targets are badly needed. This review examines the current state of treatments and emerging therapeutics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Nintedanib was found to significantly reduce the rate of decline in SSc associated FVC, although it has no benefit on skin fibrosis. New cannabinoid receptor2 agonist has shown superb effects in phase II and results in phase III are anticipated. Other targets are currently being tested in clinical trials and new targets that are yet to be tested are increasing in the SSc literature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Nintedanib is now licenced for SSc interstitial lung disease but this does not modify the skin fibrosis. Current ongoing trials will determine the role of various targets. New targets are emerging as we gain a deeper understanding of disease pathogenesis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11926-020-00918-3","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T17:03:59Z","timestamp":1592586239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope"],"prefix":"10.1007","volume":"22","author":[{"given":"Monique","family":"Hinchcliff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7483-740X","authenticated-orcid":false,"given":"Steven","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"issue":"10103","key":"918_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685\u201399.","journal-title":"Lancet"},{"issue":"5","key":"918_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.molmed.2019.02.001","volume":"25","author":"J Henderson","year":"2019","unstructured":"Henderson J, Distler J, O\u2019Reilly S. The role of epigenetic modifications in systemic sclerosis: a druggable target. Trends Mol Med. 2019;25(5):395\u2013411.","journal-title":"Trends Mol Med"},{"issue":"9","key":"918_CR3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","volume":"51","author":"S O\u2019Reilly","year":"2012","unstructured":"O\u2019Reilly S, H\u00fcgle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology. 2012;51(9):1540\u20139.","journal-title":"Rheumatology"},{"issue":"420","key":"918_CR4","doi-asserted-by":"publisher","first-page":"eaal3765","DOI":"10.1126\/scitranslmed.aal3765","volume":"9","author":"D Lagares","year":"2017","unstructured":"Lagares D, et al. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. Sci Transl Med. 2017;9(420):eaal3765.","journal-title":"Sci Transl Med"},{"issue":"24","key":"918_CR5","doi-asserted-by":"publisher","first-page":"9448","DOI":"10.1073\/pnas.1201840109","volume":"109","author":"T Kisseleva","year":"2012","unstructured":"Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci. 2012;109(24):9448\u201353.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"918_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.coph.2013.05.016","volume":"13","author":"M Antic","year":"2013","unstructured":"Antic M, Distler JHW, Distler O. Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise? Curr Opin Pharmacol. 2013;13(3):455\u201362.","journal-title":"Curr Opin Pharmacol"},{"issue":"01","key":"918_CR7","doi-asserted-by":"publisher","first-page":"087","DOI":"10.1055\/s-0036-1571295","volume":"36","author":"YJ Yoon","year":"2016","unstructured":"Yoon YJ, Friedman SL, Lee YA. Antifibrotic therapies: where are we now? Semin Liver Dis. 2016;36(01):087\u201398.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"918_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199\u2013210.","journal-title":"J Pathol"},{"issue":"6","key":"918_CR9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse R, Clevers H. Wnt\/\u03b2-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985\u201399.","journal-title":"Cell"},{"issue":"1","key":"918_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0092-8674(82)90409-3","volume":"31","author":"R Nusse","year":"1982","unstructured":"Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31(1):99\u2013109.","journal-title":"Cell"},{"issue":"589","key":"918_CR11","doi-asserted-by":"publisher","first-page":"eaay4494","DOI":"10.1126\/scisignal.aay4494","volume":"12","author":"CK Mirabelli","year":"2019","unstructured":"Mirabelli CK, et al. Perspectives on the role of Wnt biology in cancer. Sci Signal. 2019;12(589):eaay4494.","journal-title":"Sci Signal"},{"issue":"7","key":"918_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrneph.2016.54","volume":"12","author":"M Edeling","year":"2016","unstructured":"Edeling M, Ragi G, Huang S, Pavenst\u00e4dt H, Susztak K. Developmental signalling pathways in renal fibrosis: the roles of notch, Wnt and Hedgehog. Nat Rev Nephrol. 2016;12(7):426\u201339.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"918_CR13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s10067-018-4298-5","volume":"38","author":"J Frost","year":"2019","unstructured":"Frost J, Estivill X, Ramsay M, Tikly M. Dysregulation of the Wnt signaling pathway in South African patients with diffuse systemic sclerosis. Clin Rheumatol. 2019;38(3):933\u20138.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"918_CR14","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/path.4481","volume":"235","author":"E Hamburg-Shields","year":"2015","unstructured":"Hamburg-Shields E, DiNuoscio GJ, Mullin NK, Lafyatis R, Atit RP. Sustained \u03b2-catenin activity in dermal fibroblasts promotes fibrosis by up-regulating expression of extracellular matrix protein-coding genes. J Pathol. 2015;235(5):686\u201397.","journal-title":"J Pathol"},{"issue":"8","key":"918_CR15","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1002\/art.34424","volume":"64","author":"J Wei","year":"2012","unstructured":"Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, et al. Wnt\/\u03b2-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum. 2012;64(8):2734\u201345.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"918_CR16","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.jid.2017.06.032","volume":"137","author":"R Lafyatis","year":"2017","unstructured":"Lafyatis R, Mantero JC, Gordon J, Kishore N, Carns M, Dittrich H, et al. Inhibition of \u03b2-catenin signaling in the skin rescues cutaneous adipogenesis in systemic sclerosis: a randomized, double-blind, placebo-controlled trial of C-82. J Investig Dermatol. 2017;137(12):2473\u201383.","journal-title":"J Investig Dermatol"},{"issue":"5","key":"918_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.tips.2015.02.008","volume":"36","author":"M Maccarrone","year":"2015","unstructured":"Maccarrone M, Bab I, B\u00edr\u00f3 T, Cabral GA, Dey SK, di Marzo V, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36(5):277\u201396.","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"918_CR18","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/rheumatology\/kep189","volume":"48","author":"E Garcia-Gonzalez","year":"2009","unstructured":"Garcia-Gonzalez E, Selvi E, Balistreri E, Lorenzini S, Maggio R, Natale MR, et al. Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology. 2009;48(9):1050\u20136.","journal-title":"Rheumatology"},{"issue":"4","key":"918_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/ard.2010.137539","volume":"70","author":"E Balistreri","year":"2011","unstructured":"Balistreri E, Garcia-Gonzalez E, Selvi E, Akhmetshina A, Palumbo K, Lorenzini S, et al. The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model. Ann Rheum Dis. 2011;70(4):695\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"61","key":"918_CR20","doi-asserted-by":"publisher","first-page":"103486","DOI":"10.18632\/oncotarget.21975","volume":"8","author":"Q Fu","year":"2017","unstructured":"Fu Q, et al. Activation of cannabinoid receptor type 2 by JWH133 alleviates bleomycin-induced pulmonary fibrosis in mice. Oncotarget. 2017;8(61):103486\u201398.","journal-title":"Oncotarget"},{"issue":"1","key":"918_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12931-016-0373-0","volume":"17","author":"M Lucattelli","year":"2016","unstructured":"Lucattelli M, Fineschi S, Selvi E, Garcia Gonzalez E, Bartalesi B, de Cunto G, et al. Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung. Respir Res. 2016;17(1):49.","journal-title":"Respir Res"},{"issue":"5","key":"918_CR22","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1084\/jem.20101629","volume":"208","author":"C Dees","year":"2011","unstructured":"Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med. 2011;208(5):961\u201372.","journal-title":"J Exp Med"},{"issue":"3","key":"918_CR23","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2353\/ajpath.2006.050767","volume":"169","author":"RG Ruddell","year":"2006","unstructured":"Ruddell RG, Oakley F, Hussain Z, Yeung I, Bryan-Lluka LJ, Ramm GA, et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol. 2006;169(3):861\u201376.","journal-title":"Am J Pathol"},{"issue":"12","key":"918_CR24","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/nm.2490","volume":"17","author":"MR Ebrahimkhani","year":"2011","unstructured":"Ebrahimkhani MR, Oakley F, Murphy LB, Mann J, Moles A, Perugorria MJ, et al. Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease. Nat Med. 2011;17(12):1668\u201373.","journal-title":"Nat Med"},{"issue":"9","key":"918_CR25","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1096\/fj.08-128736","volume":"23","author":"AK Ghosh","year":"2009","unstructured":"Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, et al. Peroxisome proliferator-activated receptor-\u03b3 abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J. 2009;23(9):2968\u201377.","journal-title":"FASEB J"},{"issue":"11","key":"918_CR26","doi-asserted-by":"publisher","first-page":"e13778","DOI":"10.1371\/journal.pone.0013778","volume":"5","author":"J Wei","year":"2010","unstructured":"Wei J, Ghosh AK, Sargent JL, Komura K, Wu M, Huang QQ, et al. PPAR\u03b3 Downregulation by TGF\u00df in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One. 2010;5(11):e13778.","journal-title":"PLoS One"},{"issue":"2","key":"918_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2353\/ajpath.2009.080574","volume":"174","author":"M Wu","year":"2009","unstructured":"Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol. 2009;174(2):519\u201333.","journal-title":"Am J Pathol"},{"issue":"6","key":"918_CR28","first-page":"L1146","volume":"288","author":"HA Burgess","year":"2005","unstructured":"Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M, et al. PPAR\u03b3 agonists inhibit TGF-\u03b2 induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Phys Lung Cell Mol Phys. 2005;288(6):L1146\u201353.","journal-title":"Am J Phys Lung Cell Mol Phys"},{"issue":"12","key":"918_CR29","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","volume":"75","author":"N Ruzehaji","year":"2016","unstructured":"Ruzehaji N, Frantz C, Ponsoye M, Avouac J, Pezet S, Guilbert T, et al. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann Rheum Dis. 2016;75(12):2175\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"918_CR30","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1136\/annrheumdis-2016-210821","volume":"76","author":"J Avouac","year":"2017","unstructured":"Avouac J, Konstantinova I, Guignabert C, Pezet S, Sadoine J, Guilbert T, et al. Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017;76(11):1931\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"918_CR31","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm1579","volume":"13","author":"SE Mullican","year":"2007","unstructured":"Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J, et al. Abrogation of nuclear receptors Nr4a3 andNr4a1 leads to development of acute myeloid leukemia. Nat Med. 2007;13(6):730\u20135.","journal-title":"Nat Med"},{"issue":"2","key":"918_CR32","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nm.3777","volume":"21","author":"K Palumbo-Zerr","year":"2015","unstructured":"Palumbo-Zerr K, Zerr P, Distler A, Fliehr J, Mancuso R, Huang J, et al. Orphan nuclear receptor NR4A1 regulates transforming growth factor-\u03b2 signaling and fibrosis. Nat Med. 2015;21(2):150\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"918_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cytogfr.2012.04.003","volume":"23","author":"S O\u2019Reilly","year":"2012","unstructured":"O\u2019Reilly S, Ciechomska M, Cant R, H\u00fcgle T, van Laar JM. Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev. 2012;23(3):99\u2013107.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7","key":"918_CR34","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","volume":"71","author":"K Khan","year":"2012","unstructured":"Khan K, Xu S, Nihtyanova S, Derrett-Smith E, Abraham D, Denton CP, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis. 2012;71(7):1235\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"918_CR35","doi-asserted-by":"publisher","first-page":"9952","DOI":"10.1074\/jbc.M113.545822","volume":"289","author":"S O\u2019Reilly","year":"2014","unstructured":"O\u2019Reilly S, Ciechomska M, Cant R, van Laar JM. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-\u03b2 (TGF-\u03b2) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem. 2014;289(14):9952\u201360.","journal-title":"J Biol Chem"},{"issue":"4","key":"918_CR36","first-page":"e4-e4","volume":"2","author":"S O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly S, Cant R, Ciechomska M, van Laar JM. Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunol. 2013;2(4):e4-e4.","journal-title":"Clin Transl Immunol"},{"issue":"1","key":"918_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","volume":"180","author":"S Kitaba","year":"2012","unstructured":"Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol. 2012;180(1):165\u201376.","journal-title":"Am J Pathol"},{"issue":"12","key":"918_CR38","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","volume":"49","author":"Y Shima","year":"2010","unstructured":"Shima Y, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford). 2010;49(12):2408\u201312.","journal-title":"Rheumatology (Oxford)"},{"issue":"10038","key":"918_CR39","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630\u201340.","journal-title":"Lancet"},{"issue":"2","key":"918_CR40","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"D Khanna","year":"2018","unstructured":"Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018;77(2):212\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"918_CR41","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","volume":"77","author":"CP Denton","year":"2018","unstructured":"Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, et al. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis. 2018;77(9):1362\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"918_CR42","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/biof.1117","volume":"39","author":"S O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly S. Role of interleukin-13 in fibrosis, particularly systemic sclerosis. BioFactors. 2013;39(6):593\u20136.","journal-title":"BioFactors"},{"issue":"2","key":"918_CR43","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/art.37738","volume":"65","author":"T H\u00fcgle","year":"2013","unstructured":"H\u00fcgle T, O\u2019Reilly S, Simpson R, Kraaij MD, Bigley V, Collin M, et al. Tumor necrosis factor\u2013costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthritis Rheum. 2013;65(2):481\u201391.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"918_CR44","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/art.37706","volume":"65","author":"P Fuschiotti","year":"2013","unstructured":"Fuschiotti P, Larregina AT, Ho J, Feghali-Bostwick C, Medsger TA Jr. Interleukin-13\u2013producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum. 2013;65(1):236\u201346.","journal-title":"Arthritis Rheum"},{"key":"918_CR45","doi-asserted-by":"crossref","unstructured":"Raghu G, Richeldi L, Crestani B, Wung P, Bejuit R, Esperet C, et al. SAR156597 in idiopathic pulmonary fibrosis: a phase 2, placebo-controlled study (DRI11772). Eur Respir J. 2018:1801130.","DOI":"10.1183\/13993003.01130-2018"},{"issue":"7","key":"918_CR46","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/ni1084","volume":"5","author":"SR Dillon","year":"2004","unstructured":"Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5(7):752\u201360.","journal-title":"Nat Immunol"},{"issue":"8","key":"918_CR47","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/1346-8138.14934","volume":"46","author":"R Mihara","year":"2019","unstructured":"Mihara R, Kabashima K, Furue M, Nakano M, Ruzicka T. Nemolizumab in moderate to severe atopic dermatitis: an exploratory analysis of work productivity and activity impairment in a randomized phase II study. J Dermatol. 2019;46(8):662\u201371.","journal-title":"J Dermatol"},{"issue":"5","key":"918_CR48","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2014-207109","volume":"75","author":"J Huang","year":"2016","unstructured":"Huang J, Beyer C, Palumbo-Zerr K, Zhang Y, Ramming A, Distler A, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2016;75(5):883\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"918_CR49","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328.","journal-title":"N Engl J Med"},{"issue":"10","key":"918_CR50","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s40265-013-0080-9","volume":"73","author":"GM Keating","year":"2013","unstructured":"Keating GM. Abatacept: a review of its use in the management of rheumatoid arthritis. Drugs. 2013;73(10):1095\u2013119.","journal-title":"Drugs"},{"issue":"1","key":"918_CR51","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/art.41055","volume":"72","author":"D Khanna","year":"2020","unstructured":"Khanna D, et al. Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase ii investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2020;72(1):125\u201336.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"918_CR52","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49(2):271\u201380.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"918_CR53","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","volume":"74","author":"S Jordan","year":"2015","unstructured":"Jordan S, Distler JH, Maurer B, Huscher D, van Laar J, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"918_CR54","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","volume":"78","author":"M Elhai","year":"2019","unstructured":"Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78(7):979\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"918_CR55","doi-asserted-by":"publisher","first-page":"R57-R57","DOI":"10.1186\/ar4492","volume":"16","author":"A Goldberg","year":"2014","unstructured":"Goldberg A, Geppert T, Schiopu E, Frech T, Hsu V, Simms RW, et al. Dose-escalation of human anti-interferon-\u03b1 receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014;16(1):R57-R57.","journal-title":"Arthritis Res Ther"},{"key":"918_CR56","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3389\/fimmu.2018.01896","volume":"9","author":"N Kavian","year":"2018","unstructured":"Kavian N, Mehlal S, Jeljeli M, Saidu NEB, Nicco C, Cerles O, et al. The Nrf2-antioxidant response element signaling pathway controls fibrosis and autoimmunity in scleroderma. Front Immunol. 2018;9:1896.","journal-title":"Front Immunol"},{"issue":"4","key":"918_CR57","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0002-9440(10)63215-4","volume":"164","author":"Y Asano","year":"2004","unstructured":"Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts. Am J Pathol. 2004;164(4):1275\u201392.","journal-title":"Am J Pathol"},{"issue":"11","key":"918_CR58","doi-asserted-by":"publisher","first-page":"7708","DOI":"10.4049\/jimmunol.175.11.7708","volume":"175","author":"Y Asano","year":"2005","unstructured":"Asano Y, et al. Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol. 2005;175(11):7708\u201318.","journal-title":"J Immunol"},{"issue":"9865","key":"918_CR59","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451\u201360.","journal-title":"Lancet"},{"key":"918_CR60","doi-asserted-by":"crossref","unstructured":"Kitanaga Y, et al. In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. Rheumatology (Oxford). 2019:kez526.","DOI":"10.1093\/rheumatology\/kez526"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00918-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-020-00918-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00918-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T18:11:18Z","timestamp":1650219078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-020-00918-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1007\/s11926-020-00918-3","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,19]]},"assertion":[{"value":"19 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"42"}}